The briefing
German-led researchers report encouraging long-term clinical results for a vaccine targeting a common genetic mutation in malignant brain tumors. The study associates mutation-specific immunotherapy with survival gains over an eight-year follow-up.
Original headline
Brain tumor vaccine links mutation targeting to eight-year survival gains